APA

Younossi Z. M., Stepanova M., Jacobson I. M., Asselah T., Gane E. J., Lawitz E., Foster G. R., Roberts S. K., Thompson A. J., Willems B. E., Welzel T. M., Pearlman B., Younossi I., Racila A. & Henry L. (20180521). Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. : Alimentary pharmacology & therapeutics.

Chicago

Younossi Z M, Stepanova M, Jacobson I M, Asselah T, Gane E J, Lawitz E, Foster G R, Roberts S K, Thompson A J, Willems B E, Welzel T M, Pearlman B, Younossi I, Racila A and Henry L. 20180521. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. : Alimentary pharmacology & therapeutics.

Harvard

Younossi Z. M., Stepanova M., Jacobson I. M., Asselah T., Gane E. J., Lawitz E., Foster G. R., Roberts S. K., Thompson A. J., Willems B. E., Welzel T. M., Pearlman B., Younossi I., Racila A. and Henry L. (20180521). Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. : Alimentary pharmacology & therapeutics.

MLA

Younossi Z M, Stepanova M, Jacobson I M, Asselah T, Gane E J, Lawitz E, Foster G R, Roberts S K, Thompson A J, Willems B E, Welzel T M, Pearlman B, Younossi I, Racila A and Henry L. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. : Alimentary pharmacology & therapeutics. 20180521.